/

Sociétés

Ne

Non vérifié

Neurim Pharmaceuticals

Ce que nous écrivons

ÉconomieEnfanceIndustrie pharmaceutiqueSanté PubliqueStart-up

3 communiqués de presse

Voir tous les communiqués de presse

26/03/2025

Industrie pharmaceutique

Santé Publique

Enfance

NEURIM PHARMACEUTICALS RICEVE L'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO IN EUROPA PER LA MELATONINA A RILASCIO PROLUNGATO PEDIATRICA (SLENYTO®) PER IL TRATTAMENTO DELL'INSONNIA NEI BAMBINI AFFETTI DA DISTURBO DA DEFICIT DI ATTENZIONE E IPERATTIVITÀ (ADHD)

Source

Neurim Pharmaceuticals

Émetteur

1.00

0

26/03/2025

Industrie pharmaceutique

Santé Publique

Enfance

NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Source

Neurim Pharmaceuticals

Émetteur

1.00

0

30/07/2024

Industrie pharmaceutique

Santé Publique

Économie

Start-up

Enfance

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

Source

Neurim Pharmaceuticals

Émetteur

1.00

0

Followers

0

Compatibilité

0